for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bristol-Myers Squibb Co

BMY.N

Latest Trade

59.14USD

Change

-0.29(-0.49%)

Volume

2,387,704

Today's Range

58.75

 - 

59.63

52 Week Range

42.49

 - 

68.34

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Nurix Therapeutics Files For IPO Of Up To $100 Million

July 2 (Reuters) - :NURIX THERAPEUTICS FILES FOR IPO OF UP TO $100 MILLION - SEC FILING.NURIX THERAPEUTICS - J.P. MORGAN, PIPER SANDLER, STIFEL, NEEDHAM & COMPANY ARE AMONG UNDERWRITERS TO IPO.NURIX THERAPEUTICS - HAVE APPLIED TO LIST CO'S COMMON STOCK ON NASDAQ GLOBAL MARKET UNDER SYMBOL “NRIX".NURIX THERAPEUTICS - BRISTOL-MYERS SQUIBB BENEFICIALLY OWNS 6.2% STAKE IN CO PRIOR TO IPO.NURIX THERAPEUTICS - FORESITE CAPITAL FUND IV LP BENEFICIALLY OWNS 7.5% STAKE IN CO PRIOR TO IPO.

Agios And Royalty Pharma Announce $255 Mln Purchase Agreement For IDHIFA Royalty

June 12 (Reuters) - Agios Pharmaceuticals Inc <AGIO.O>::AGIOS AND ROYALTY PHARMA ANNOUNCE $255 MILLION PURCHASE AGREEMENT FOR IDHIFA® ROYALTY.AGIOS PHARMACEUTICALS - RETAINS RIGHT TO RECEIVE $25 MILLION PAYMENT UPON ACHIEVEMENT OF A SPECIFIED EX-U.S. COMMERCIAL MILESTONE EVENT.AGIOS PHARMACEUTICALS - CO HAS SOLD ITS TIERED, SALES-BASED ROYALTY RIGHTS ON WORLDWIDE NET SALES OF BRISTOL MYERS SQUIBB'S IDHIFA.AGIOS - WILL CONTINUE TO CO-PROMOTE IDHIFA, RECEIVE REIMBURSEMENT FROM BRISTOL MYERS FOR CO-PROMOTION UNDER ITS 2010 AGREEMENT WITH CELGENE.

Bristol-Myers Squibb Says Declared Quarterly Dividend Of Forty-Five Cents Per Share On $.10 Par Value Common Stock Of Corp

June 11 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL-MYERS SQUIBB CO - DECLARED A QUARTERLY DIVIDEND OF FORTY-FIVE CENTS PER SHARE ON $.10 PAR VALUE COMMON STOCK OF CORPORATION.

U.S. FDA Approves Opdivo (Nivolumab) For The Treatment Of Patients With Advanced Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- And Platinum-Based Chemotherapy

June 10 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::U.S. FOOD AND DRUG ADMINISTRATION APPROVES OPDIVO® (NIVOLUMAB) FOR THE TREATMENT OF PATIENTS WITH ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) AFTER PRIOR FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY.APPLICATION WAS GRANTED PRIORITY REVIEW DESIGNATION BY FDA, AND APPROVAL IS BASED ON PHASE 3 ATTRACTION-3 TRIAL.

Bristol-Myers - New Data Reinforce Durable Clinical Responses Of Orencia In Early Rheumatoid Arthritis

June 3 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::NEW DATA REINFORCE IMPROVED AND DURABLE CLINICAL RESPONSES OF ORENCIA IN MODERATE-TO-SEVERE EARLY RHEUMATOID ARTHRITIS PATIENTS WITH AUTOANTIBODIES LINKED TO MORE SEVERE DISEASE.BRISTOL-MYERS SQUIBB CO - SEROPOSITIVE PATIENTS SWITCHING FROM ADALIMUMAB TO ORENCIA SHOWED TREND TOWARD HIGHER EFFICACY AT WEEK 48.BRISTOL-MYERS - AMONG 76 SEROPOSITIVE RA PATIENTS WHO ENTERED OPEN-LABEL SWITCH PERIOD OVERALL SAFETY PROFILE OF ORENCIA WAS CONSISTENT WITH PRIOR STUDIES.

Bristol Myers Announces Results From Phase 3 Zeposia Study In Ulcerative Colitis

June 2 (Reuters) - BRISTOL MYERS::BRISTOL MYERS - ANNOUNCES TOPLINE RESULTS FROM PHASE 3 TRUE NORTH TRIAL EVALUATING ZEPOSIA IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS.BRISTOL MYERS - PHASE 3 TRUE NORTH ZEPOSIA TRIAL ALSO MET KEY SECONDARY ENDPOINTS OF CLINICAL RESPONSE AND ENDOSCOPIC IMPROVEMENT.BRISTOL MYERS - PHASE 3 TRUE NORTH ZEPOSIA TRIAL MET PRIMARY ENDPOINTS OF CLINICAL REMISSION IN INDUCTION AT WEEK 10, IN MAINTENANCE AT WEEK 52.BRISTOL MYERS - SAFETY PROFILE OF ZEPOSIA IN PHASE 3 TRUE NORTH TRIAL WAS CONSISTENT WITH PREVIOUSLY REPORTED TRIALS.

Compugen Reports FDA Clearance Of IND Application For Phase 1/2 Triple Combination Study Of COM701

June 1 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR PHASE 1/2 TRIPLE COMBINATION STUDY OF COM701 WITH BRISTOL MYERS SQUIBB'S OPDIVO® (NIVOLUMAB) AND TIGIT INHIBITOR.COMPUGEN - ON-TRACK TO BEGIN TRIPLE COMBINATION STUDY DURING SECOND HALF OF 2020.COMPUGEN - COM701 TRIPLE COMBINATION STUDY TO EVALUATE SIMULTANEOUS BLOCKADE OF PVRIG, TIGIT & PD-1 IMMUNE CHECKPOINTS.

U.S. FDA Approves Opdivo, Yervoy With Limited Chemotherapy As First-Line Treatment Of Metastatic Or Recurrent Non-Small Cell Lung Cancer

May 26 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::U.S. FOOD AND DRUG ADMINISTRATION APPROVES OPDIVO® (NIVOLUMAB) + YERVOY® (IPILIMUMAB) COMBINED WITH LIMITED CHEMOTHERAPY AS FIRST-LINE TREATMENT OF METASTATIC OR RECURRENT NON-SMALL CELL LUNG CANCER.BRISTOL-MYERS SQUIBB - IN CHECKMATE -9LA, OPDIVO + YERVOY WITH TWO CYCLES OF CHEMOTHERAPY DEMONSTRATED SUPERIOR OVERALL SURVIVAL VERSUS CHEMOTHERAPY.

Repare Therapeutics Enters Into Research Collaboration With Bristol Myers Squibb

May 26 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::REPARE THERAPEUTICS - ENTERED INTO EXCLUSIVE, WORLDWIDE RESEARCH COLLABORATION WITH BRISTOL MYERS SQUIBB.REPARE THERAPEUTICS - BRISTOL MYERS TO LEVERAGE CO'S PROPRIETARY SNIPRX SYNTHETIC LETHAL DISCOVERY PLATFORM.REPARE THERAPEUTICS - BMS WILL MAKE AN UPFRONT PAYMENT OF $65 MILLION WHICH INCLUDES A $15 MILLION EQUITY INVESTMENT IN CO.REPARE THERAPEUTICS - UNDER COLLABORATION, CO ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES AND ROYALTIES.REPARE - WILL GRANT BMS EXCLUSIVE RIGHTS TO DEVELOP, COMMERCIALIZE THERAPEUTICS FOR SELECT VALIDATED SYNTHETIC LETHAL PRECISION ONCOLOGY TARGETS.REPARE THERAPEUTICS - WILL BE ELIGIBLE TO RECEIVE UP TO ABOUT $3 BILLION IN LICENSE FEES, DISCOVERY, DEVELOPMENT, REGULATORY AND SALES-BASED MILESTONES.

FDA Approves Nivolumab Plus Ipilimumab For First-Line Metastatic Non-Small Cell Lung Cancer

May 15 (Reuters) - U.S. Food and Drug Administration::FDA - APPROVES BRISTOL-MYERS SQUIBB' NIVOLUMAB PLUS IPILIMUMAB FOR FIRST-LINE METASTATIC NON-SMALL CELL LUNG CANCER (PD-L1 TUMOR EXPRESSION ≥1%).FDA - APPROVED PD-L1 IHC 28-8 PHARMDX AS A COMPANION DIAGNOSTIC DEVICE FOR SELECTING PATIENTS WITH NSCLC FOR TREATMENT WITH NIVOLUMAB PLUS IPILIMUMAB.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up